Clearmind Medicine Announces 1-for-10 Reverse Stock Split to Maintain Nasdaq Listing
CMND is trading near its 52-week low of $0.341 (10% below the low) on elevated volume (12× avg).
Summary
Clearmind Medicine announced a 1-for-10 reverse stock split, effective May 21, 2026, to meet Nasdaq's minimum bid price requirement and avoid delisting.
Key Events · Corporate Governance and Compliance · CMND
-
1-for-10 Reverse Stock Split Announced
The company will effect a 1-for-10 reverse share split, consolidating every ten common shares into one, effective May 21, 2026.
-
Nasdaq Compliance Objective
The primary purpose of the reverse split is to regain compliance with the Nasdaq Minimum Bid Price Rule, as the stock is trading near its 52-week low.
-
Share Count Adjustment
The number of issued and outstanding common shares will decrease from 10,190,337 to approximately 1,019,033. Authorized share capital remains unchanged.
-
Fractional Shares Rounded Up
No fractional shares will be issued; all fractional shares will be rounded up to the nearest whole common share.
Analysis · CMND · Life Sciences
Clearmind Medicine is implementing a 1-for-10 reverse stock split, effective May 21, 2026, primarily to regain compliance with the Nasdaq Minimum Bid Price Rule. This action is critical for the company's continued listing on Nasdaq, as its stock is currently trading near its 52-week low. While necessary for compliance, reverse splits are generally viewed negatively by the market as they often indicate a company's struggle with a declining share price and can lead to reduced liquidity.
At the time of this filing, CMND was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $794K. The 52-week trading range was $0.34 to $52.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.